您当前的位置: 首页 > 采集报告
根据IQVIA 2019年展望报告,预计到2023年全球医药市场规模将达到1.5万亿美元,未来五年的年复合增长率为3-6%,明显低于前五年的6.3%增速。发达成熟市场的欧洲前五大市场的增速将降至1-4%,日本总体增速预期为3-0%。2018年,整个新兴医药市场规模达到2860亿美元,增速为6.9%,其2014-2018年五年复合增长率达到了9.3%,超过美国的7.2%以及全球均值6.3%;预计到2023年,新兴市场整体规模将达到3550-3850亿美元,年复合增长率为5-8%,超过全球平均增速。 以中东与北非地区(MENA)、撒哈拉以南非洲国家(SSA)、拉丁美洲地区(LATM)以及俄罗斯为代表的新兴市场呈现出较快增长势头,并已受到全球制药企业的广泛关注。经济发展、人口数量增加、城市化和生活方式西化、不断增长的诊疗率、急性病逐步转为慢性病、不断扩大的医疗服务和保障体系等因素将进一步驱动这些区域药品消费的快速增长。本文将就上述四个地区/国家的市场机会、准入与挑战进行讨论。 查看详细>>
来源:科睿唯安 点击量:582Anyone thinking that 2020 might travel down apredictable path for the biopharma sector was swiftly disabused of this view in the opening weeks of the year.The coronavirus pandemic has changed the focus for almost every drug developer,whether they are working on potential treatments or trying to keep their businesses on track–or both. 查看详细>>
来源:EvaluatePharma 点击量:231The COVID-19 pandemic is having deep and lasting impact on the U.S.healthcare system,causing shifts in the demand for drugs in hospitals and the community,in the delivery of care beyond COVID-19,in medical and drug coverage,and in the acceleration of efforts to develop new therapies and vaccines. 查看详细>>
来源:IQVIA 点击量:232The regulatory pathway to approve‘biosimilar’competitors was signed into U.S.law in 2010,but savings have been slow to materialize until recently.Earlybiosimilars have been few in number and generated limited savings compared to expectations.Slower uptake and muted savings raise fundamental questionsaround defining the success of biosimilars for all stakeholders,and particularly patients.By contrast,recent events suggest an inflection has occurred and eventsexpected in the next few years potentially offer to bring further significant shifts. 查看详细>>
来源:IQVIA 点击量:221令和2年度第2回の医療分野における研究開発関連の調整費については、「医療分野の研究開発関連の調整費に関する配分方針」(平成26年6月10日健康?医療戦略推進本部決定)に基づき、総額で95.5億円を配分。そのうち36.7億円を新型コロナウイルス感染症研究開発を更に加速?拡充するとともに、研究開発体制のポストコロナ時代への対応も支援する。?また、新型コロナウイルス感染症対策予備費を活用し、早期?大量の感染症検査の実現に向けた研究開発(19.0億円)を支援する。 查看详细>>
来源:日本健康医疗战略推进总部 点击量:227The pandemic ensured that 2020 was unlike any other year for biopharma and medtech companies.But,while these sectors turned their collective attentions to vanquishing the novel coronavirus,the usual business of drug and device development continued alongside.This report is around-up of Evaluate Vantage’s analyses of 2020–from M&A,venture financing and IPO markets,In many ways Covid-19 turbocharged an industry that was already riding fairly high.The financing climate had been strong for afew years,but 2020 saw records broken in the venture and IPO worlds.With the spotlight on biopharma,which made remarkably swift progress on apipeline of pandemic therapies,investors rushed to inject money into the sector. 查看详细>>
来源:美国研究制药工业协会 点击量:127